Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on Loading, Release, and Delivery of Mitoxantrone in Hypoxic Cancer Cells

Overview

Journal Sci Rep

Specialty Science

Date 2017 May 25

PMID 28536462

Citations 15

Authors

Amit Wani

Galbokka H Layan Savithra

Ayat Abyad

Shrey Kanvinde

Jing Li

Stephanie Brock

David Oupicky

Affiliations

Soon will be listed here.

Abstract

Mesoporous silica nanomaterials show great potential to deliver chemotherapeutics for cancer treatment. The key challenges in the development of injectable mesoporous silica formulations are colloidal instability, hemolysis and inefficient drug loading and release. In this study, we evaluated the effect of PEGylation of mesoporous silica nanorods (MSNR) on hemolysis, colloidal stability, mitoxantrone (MTX) loading, in vitro MTX release, and cellular MTX delivery under hypoxic conditions. We found that PEGylation prevented dose-dependent hemolysis in the concentrations studied (0-10 mg/ml) and improved colloidal stability of MSNR. A negative effect of PEGylation on MTX loading was observed but PEGylated MSNR (PMSNR) demonstrated increased MTX release compared to non-PEGylated particles. Under hypoxic conditions, a decrease in the IC50 of MTX and MTX-loaded MSNR was observed when compared to normoxic conditions. These results showed that MSNR could deliver the chemotherapeutic agent, MTX to tumor cells and induce effective cell killing. However, the effect of PEGylation needs to be carefully studied due to the observed adverse effect on drug loading.

Citing Articles

Synthesis of Bovine Serum Albumin-Coated Magnetic Single-Walled Carbon Nanotubes as a Delivery System for Mitoxantrone.

Aydin B, Bozoglu S, Karatepe N, Guner F ACS Omega. 2025; 10(1):102-113.

PMID: 39829559 PMC: 11740624. DOI: 10.1021/acsomega.3c09608.

How do lipid-based drug delivery systems affect the pharmacokinetic and tissue distribution of amiodarone? A comparative study of liposomes, solid lipid nanoparticles, and nanoemulsions.

Khaleseh F, Barzegar-Jalali M, Zakeri-Milani P, Karami Z, Saghatchi Zanjani M, Valizadeh H Iran J Basic Med Sci. 2024; 27(7):857-867.

PMID: 38800017 PMC: 11127074. DOI: 10.22038/IJBMS.2024.75152.16292.

Hybridized quantum dot, silica, and gold nanoparticles for targeted chemo-radiotherapy in colorectal cancer theranostics.

Abrishami A, Bahrami A, Nekooei S, Saljooghi A, Matin M Commun Biol. 2024; 7(1):393.

PMID: 38561432 PMC: 10984983. DOI: 10.1038/s42003-024-06043-6.

State of the Art of Silica Nanoparticles: An Overview on Biodistribution and Preclinical Toxicity Studies.

Yu J, Dan N, Eslami S, Lu X AAPS J. 2024; 26(3):35.

PMID: 38514482 DOI: 10.1208/s12248-024-00906-w.

Advanced hybrid silica nanoparticles with pH-responsive diblock copolymer brushes: optimized design for controlled doxorubicin loading and release in cancer therapy.

Lahmadi S, Alamery S, Beagan A, Alotaibi K, Alswieleh A RSC Adv. 2024; 14(13):8819-8828.

PMID: 38495996 PMC: 10941263. DOI: 10.1039/d4ra00282b.

References

Kostrzewa-Nowak D, Paine M, Korytowska A, Serwatka K, Piotrowska S, Wolf C . Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells. Cancer Lett. 2006; 245(1-2):252-62. DOI: 10.1016/j.canlet.2006.01.012. View

Riikonen J, Makila E, Salonen J, Lehto V . Determination of the physical state of drug molecules in mesoporous silicon with different surface chemistries. Langmuir. 2009; 25(11):6137-42. DOI: 10.1021/la804055s. View

He Q, Zhang J, Shi J, Zhu Z, Zhang L, Bu W . The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials. 2009; 31(6):1085-92. DOI: 10.1016/j.biomaterials.2009.10.046. View

Slowing I, Vivero-Escoto J, Wu C, Lin V . Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60(11):1278-1288. DOI: 10.1016/j.addr.2008.03.012. View

Slowing I, Wu C, Vivero-Escoto J, Lin V . Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small. 2008; 5(1):57-62. DOI: 10.1002/smll.200800926. View

Meng H, Xue M, Xia T, Ji Z, Tarn D, Zink J . Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano. 2011; 5(5):4131-44. PMC: 3905975. DOI: 10.1021/nn200809t. View

Vooturi S, Dewal M, Firestine S . Examination of a synthetic benzophenone membrane-targeted antibiotic. Org Biomol Chem. 2011; 9(18):6367-72. DOI: 10.1039/c1ob05643c. View

Chen A, Zhang M, Wei D, Stueber D, Taratula O, Minko T . Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009; 5(23):2673-7. PMC: 2833276. DOI: 10.1002/smll.200900621. View

Champion J, Katare Y, Mitragotri S . Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release. 2007; 121(1-2):3-9. PMC: 4009069. DOI: 10.1016/j.jconrel.2007.03.022. View

10.

Patil Y, Sadhukha T, Ma L, Panyam J . Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009; 136(1):21-9. DOI: 10.1016/j.jconrel.2009.01.021. View

11.

Park J, Gu L, von Maltzahn G, Ruoslahti E, Bhatia S, Sailor M . Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater. 2009; 8(4):331-6. PMC: 3058936. DOI: 10.1038/nmat2398. View

12.

Parker B, Buley T, Evison B, Cutts S, Neumann G, Iskander M . A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J Biol Chem. 2004; 279(18):18814-23. DOI: 10.1074/jbc.M400931200. View

13.

Giri S, Trewyn B, Stellmaker M, Lin V . Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl. 2005; 44(32):5038-44. DOI: 10.1002/anie.200501819. View

14.

Liu R, Liao P, Liu J, Feng P . Responsive polymer-coated mesoporous silica as a pH-sensitive nanocarrier for controlled release. Langmuir. 2011; 27(6):3095-9. DOI: 10.1021/la104973j. View

15.

Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y . PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2009; 27(1):161-74. DOI: 10.1007/s11095-009-9992-1. View

16.

Arnida , Janat-Amsbury M, Ray A, Peterson C, Ghandehari H . Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm. 2010; 77(3):417-23. PMC: 3379889. DOI: 10.1016/j.ejpb.2010.11.010. View

17.

Toh Y, Li T . Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway. Clin Cancer Res. 2011; 17(15):5026-37. DOI: 10.1158/1078-0432.CCR-11-0235. View

18.

Perche F, Biswas S, Wang T, Zhu L, Torchilin V . Hypoxia-targeted siRNA delivery. Angew Chem Int Ed Engl. 2014; 53(13):3362-6. PMC: 4150469. DOI: 10.1002/anie.201308368. View

19.

Muro S, Garnacho C, Champion J, Leferovich J, Gajewski C, Schuchman E . Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther. 2008; 16(8):1450-8. PMC: 2810502. DOI: 10.1038/mt.2008.127. View

20.

Singh N, Karambelkar A, Gu L, Lin K, Miller J, Chen C . Bioresponsive mesoporous silica nanoparticles for triggered drug release. J Am Chem Soc. 2011; 133(49):19582-5. PMC: 3295203. DOI: 10.1021/ja206998x. View